Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race

Vertex tells “The Pink Sheet” DAILY that VX-950 has more robust data, including new numbers scheduled for release at a major medical meeting next month.